Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Multicenter and Retrospective Study
Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences &a...
Saved in:
| Main Authors: | Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-01-01
|
| Series: | Breast Cancer: Targets and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/non-luminal-disease-score-for-everolimus-in-patients-withhormone-recep-peer-reviewed-fulltext-article-BCTT |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety and Efficacy of Everolimus Plus Exemestane in Postmenopausal Women with Treatment-refractory Hormone Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Analysis from EVEREXES Taiwan Subset
by: Yuan-Ching Chang, et al.
Published: (2023-07-01) -
Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
by: Magdalena Mileva, et al.
Published: (2021-07-01) -
Efficiency of late conversion from mycophenolate mofetil to everolimus in kidney graft recipients with posttransplant malignancy
by: I. G. Kim, et al.
Published: (2018-01-01) -
Insuficiencia suprarrenal por everolimus: a propósito de un caso clínico
by: Jorge Andrés Hernández Navas
Published: (2025-03-01) -
Analysis of early use of everolimus with low-dose calcineurin inhibitors in kidney transplant recipient
by: I. G. Kim, et al.
Published: (2019-10-01)